Biotech Co.* |
Pharma Co. |
Product | Terms/Details (Date) |
|
|
|||
Align |
PDI Inc. |
Three-year deal under which PDI will provide marketing services for three oncology products from Align |
PDI initially will provide a sales team of 40 representatives; the products are Numoi- syn Lozenges and Numoisyn Liquid, for dry mouth, and Xclair, for radiation dermatitis (1/19) |
Amarillo |
Bumimedic Sdn. Bhd. (Malaysia; part of the Antah HealthCare Group) |
Bumimedic will market ABI's low-dose interferon product in Malaysia |
ABI is entitled to a series of payments through approval and production, and would get royalties on sales (1/19) |
Ciphergen |
Techcomp Holdings Ltd. (China) |
Techcomp will distribute Ciphergen's ProteinChip products in China, Singapore, Malaysia, Vietnam and Indonesia |
They also entered a product development and manufacturing deal for sample preparation technology and an associated device; Ciphergen would sell resulting products (1/17) |
Discovery |
Laureate Pharma Inc. |
Discovery is purchasing Laureate's manufacturing operations in Totowa, N.J. |
Laureate has been providing manufacturing services to Discovery for more than two years; Discovery is paying $16M in cash for the facility (12/28) |
DUSA |
Stiefel Laboratories Inc. |
Stiefel got rights to distribute DUSA's Levulan Kerastick for photodynamic therapy in dermatology in Latin America |
The deal has an initial terms of 10 years; Stiefel will take over regulatory responsibilities; terms were not disclosed (1/18) |
Geron Corp. |
Cambrex Bio Science Walkersville Inc. |
Deal for the manufacture of Geron's GRNVAC1 telomerase vaccine |
The vaccine is comprised of autologous dendritic cells loaded ex vivo with telomerase mRNA; terms of the deal were not disclosed (2/13) |
Molecular |
MDS Nordion (Canada) |
Six-year deal under which MDS will manufacture and supply Zemiva for MIPI |
The molecular imaging agent is being developed for cardiac ischemia; terms of the deal were not disclosed (2/16) |
Pharmaxis |
Nigaard Pharma A/S (Norway) |
Nigaard got marketing rights to Aridol in the Scandinavian countries |
Aridol is an asthma management tool; terms of the deal were not disclosed (1/18) |
TopoTarget |
Undisclosed company |
The unnamed company will promote TopoTarget's Savene in Austria and four Eastern European countries |
The drug is being developed for treating accidental extravasations of anthracycline drugs; launch is anticipated late in 2006 (12/22) |
Viventia |
Dowpharma |
Viventia licensed rights to use Dow's Pfenex Expression Technology in antibody production |
Viventia will use the technology in up to six compounds; Dow is entitled to milestone and royalty payments in the deal (2/14) |
|
|
|||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
